tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ATOS Stock Latest News

Atossa Therapeutics Sets 15-for-1 Reverse Stock Split
Company AnnouncementsAtossa Therapeutics Sets 15-for-1 Reverse Stock Split
4d ago
8K
ATOS
Atossa Therapeutics: FDA grants orphan designation to (Z)-endoxifen
PremiumThe Fly
Atossa Therapeutics: FDA grants orphan designation to (Z)-endoxifen
13d ago
ATOS
FDA grants Atossa Therapeutics orphan drug designation for (Z)-endoxifen
PremiumThe Fly
FDA grants Atossa Therapeutics orphan drug designation for (Z)-endoxifen
14d ago
ATOS
Atossa Therapeutics outlines strategy for lead (Z)-Endoxifen program
PremiumCompany Announcements
Atossa Therapeutics outlines strategy for lead (Z)-Endoxifen program
21d ago
8K
ATOS
Atossa Wins FDA Clearance to Advance (Z)-Endoxifen Trial
PremiumCompany Announcements
Atossa Wins FDA Clearance to Advance (Z)-Endoxifen Trial
24d ago
8K
ATOS
Atossa Therapeutics receives “Study May Proceed” letter for breast cancer study
PremiumThe FlyAtossa Therapeutics receives “Study May Proceed” letter for breast cancer study
24d ago
ATOS
Atossa Therapeutics: Buy Rating on Promising DMD Advancements and Strategic Growth Potential
Premium
Ratings
Atossa Therapeutics: Buy Rating on Promising DMD Advancements and Strategic Growth Potential
1M ago
ATOS
Promising Clinical Trial Results of Z-endoxifen Support Buy Rating for Atossa Therapeutics
Premium
Ratings
Promising Clinical Trial Results of Z-endoxifen Support Buy Rating for Atossa Therapeutics
2M ago
ATOS
Atossa Therapeutics presents four trial updates on Z-endoxifen
PremiumThe Fly
Atossa Therapeutics presents four trial updates on Z-endoxifen
2M ago
ATOS
Atossa Therapeutics receives FDA RPD designation to (Z)-Endoxifen
PremiumThe Fly
Atossa Therapeutics receives FDA RPD designation to (Z)-Endoxifen
2M ago
ATOS
Atossa Therapeutics issued U.S. patent covering endoxifen formulations
PremiumThe Fly
Atossa Therapeutics issued U.S. patent covering endoxifen formulations
2M ago
ATOS
Strategic Advancements and Regulatory Progress Boost Atossa Therapeutics’ Outlook
PremiumRatings
Strategic Advancements and Regulatory Progress Boost Atossa Therapeutics’ Outlook
2M ago
ATOS
Atossa Completes FDA Meeting on Regulatory Strategies
PremiumCompany AnnouncementsAtossa Completes FDA Meeting on Regulatory Strategies
2M ago
8K
ATOS
Atossa Therapeutics details accelerated FDA strategy to advance (Z)-endoxifen
Premium
The Fly
Atossa Therapeutics details accelerated FDA strategy to advance (Z)-endoxifen
2M ago
ATOS
Atossa Therapeutics, Insilico Medicine publish study of (Z)-endoxifen in GBM
Premium
The Fly
Atossa Therapeutics, Insilico Medicine publish study of (Z)-endoxifen in GBM
2M ago
ATOS
Atossa Therapeutics: Strategic Advancements in Breast Cancer Treatment Drive Buy Rating
PremiumRatings
Atossa Therapeutics: Strategic Advancements in Breast Cancer Treatment Drive Buy Rating
3M ago
ATOS
Atossa Therapeutics Reports Increased Q3 Losses Amid R&D Focus
PremiumCompany Announcements
Atossa Therapeutics Reports Increased Q3 Losses Amid R&D Focus
3M ago
ATOS
Atossa Therapeutics: Advancements in Z-endoxifen Development and Strategic Leadership Enhancements Drive Buy Rating
PremiumRatings
Atossa Therapeutics: Advancements in Z-endoxifen Development and Strategic Leadership Enhancements Drive Buy Rating
3M ago
ATOS
Atossa Therapeutics reports Q3 EPS (7c), consensus (7c)
PremiumThe Fly
Atossa Therapeutics reports Q3 EPS (7c), consensus (7c)
3M ago
ATOS
Atossa Therapeutics Advances Breast Cancer Treatment with (Z)-Endoxifen Study
PremiumCompany AnnouncementsAtossa Therapeutics Advances Breast Cancer Treatment with (Z)-Endoxifen Study
3M ago
ATOS
Atossa Therapeutics Appoints New Chief Financial Officer
Premium
Company Announcements
Atossa Therapeutics Appoints New Chief Financial Officer
4M ago
8K
ATOS
Atossa Therapeutics appoints Mark Daniel as CFO
Premium
The Fly
Atossa Therapeutics appoints Mark Daniel as CFO
4M ago
ATOS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >